Partner, Lawyer and Patent Agent

Béatrice T. Ngatcha is a lawyer and patent agent in Lavery’s intellectual property group. She is a patent agent registered to practice in Canada and the United States. She is also a lawyer called to the Ontario Bar and a member of the Quebec Bar (c.j.c). Béatrice holds a doctoral degree in chemistry from Université Laval and has been a post-doctoral fellow at the National Research Council in Ottawa.

Education

• J.D., University of Ottawa, 2009
• Postdoctoral studies, NRC Steacie Institute for Molecular Sciences, 1999-2000
• Ph.D. Organic/Medicinal Chemistry, Université Laval, 1999
• M.Sc. Bioorganic Chemistry, Université Laval, 1995
• “Maîtrise” Organic Chemistry, University of Yaoundé, 1992
• “License” Physics and Chemistry, University of Yaoundé, 1991

In addition to a busy patent prosecution practice serving Canadian and foreign clients, Beatrice’s expertise in sought in the areas of intellectual property litigation, trade secrets, due diligence, strategy, portfolio value building, licensing and arbitration.

Beatrice is a regular speaker on intellectual properties topics at academic and professional conferences.

Publications

• “Validité”, JurisClasseur Québec, coll. “Droit des affaires”, Propriété intellectuelle, fasc. 28, Montréal, LexisNexis Canada, loose leaf
• “Canada Federal Court of Appeal Plavix decision – A sigh of relief for pharmaceutical industry”, Quarterly Newsletter of AIPLA Chemical Practice Committee, Vol. 2, No. 1, Winter 2014
• “Utility and Sound Prediction – Lessons from the Canadian Courts”, Chemistry and the Law (a division of the American Chemical Society) Newsletter, Spring 2012
• “Good Faith Requirement During Patent Prosecution in Canada – Federal Court Clarifies its Impact on Patents”, Chemistry and the Law (a division of the American Chemical Society) Newsletter, Fall 2011
• “Data Protection in Canada – Overview and Tips”, Chemistry and the Law (a division of the American Chemical Society) Newsletter, Spring 2011
• “Canada: Re-examination Cannot Be Used To Avoid Dealing With Credibility Issues Surrounding Prior Art: Prenbec And Quadro v. Timberblade and Commissioner of Patents”, APLF IP Law Bugle, May 2010
• “Brevets de sélection: l’état du droit au Canada”, Canadian Intellectual Property Review (2010), Vol. 25, No. 1
• “Section 8 of the Patented Medicines (Notice of Compliance) Regulations: Apotex Inc. v Merck Frosst Canada Ltd.”, APLF IP Law Bugle, March 2010
• “Duty of Candour in Canadian Patent Prosecution enhanced: Lundbeck Canada Inc., H. Lundbeck a/s and Merz Pharma GmbH & Co. KGaA v. Ratiopharm Inc. and The Minister of Health”, Chemistry and the Law (a division of the American Chemical Society) Newsletter, Spring 2010
• “Bayer Inc. v. The Minister of Health and The Attorney General of Canada”, Legal Alert 2010, Vol. 28, No. 11
• “Listing of Formulation Patents – Beware: Bayer Inc. v. The Minister of Health and The Attorney General of Canada”, APLF Law IP Bugle, January 2010
• T. Ngatcha, Béatrice; Trottier, M.-C.; Poirier, D. “13C Nuclear Magnetic Resonance Spectroscopy Data of a Variety of Androsterone and epi-Androsterone derivatives Substituted at Position 3ß or/and 3a”, Current Topics in Steroids Research 2011, 8, 35
• T. Ngatcha, Béatrice; Laplante, Y.; Labrie, F.; Luu-The, V.; Poirier, D. “3ß-Alkyl Androsterones as Inhibitors of Type 3 17ß-Hydroxysteroid Dehydrogenase: Inhibitory Potency in Intact Cells, Selectivity Towards Isoforms 1, 2, 5 and 7, Binding Affinity for Steroid Receptors, and Proliferative/Antiproliferative Activities on AR+ and ER+ Cell Lines”, Mol. and Cell. Endocrinol, 2006, 248, 225-232
• T. Ngatcha, Béatrice; Luu-The, V.; Labrie, F.; Poirier, D. “Androsterone 3a-Ether and/or 3ß-Substituted Derivatives as Inhibitors of Type 3 17ß-Hydroxysteroid Dehydrogenase: Chemical Synthesis and Structure-Activity Relationship”, J. Med. Chem. 2005, 48, 5257-5268
• T. Ngatcha, Béatrice; Labrie, F.; Luu-The, V.; Poirier, D. “Androsterone C16-Substituted Derivatives: Chemical Synthesis, Inhibition of Type 3 17ß-Hydroxysteroid Dehydrogenase, Binding Affinities on Steroid Receptors and Proliferative/Antiproliferative Activities on Shionogi (AR+) Cells”, J. of Enzyme Inhibition and Med. Chem. 2002, 17(3), 155
• T. Ngatcha, Béatrice; Luu-The, V.; Poirier, D. “Androsterone 3a-Substituted Derivatives as Inhibitors of Type 3 17ß-Hydroxysteroid Dehydrogenase”, Bioorg. Med. Chem. Lett. 2000, 10, 2533
• T. Ngatcha, Béatrice; Poirier, D. “Diastereoselective Addition of Organomagnesium Reagents to 17ß-TBDMS-Dihydrotestosterone”, Synthetic Communications 1999, 29, 1065
• Chênevert, R.; T. Ngatcha, Béatrice; Rose, Y.S.; Goupil, D. “Regio and Enantioselectivity of the Enzyme-Catalized Hydrolysis of Citric Acid Derivatives”, Tetrahedron: Assymetry 1998, 9, 4325
• Dionne, P.; T. Ngatcha, Béatrice; Poirier, D. “D-Ring Allyl Derivatives of 17ß- and 17a-Estradiols: Chemical Synthesis and 13C NMR Data”, Steroids 1997, 62, 674

Conferences

• Béatrice is a frequent speaker on IP-related topics — a few titles listed below, at various institutions, academic and professional, including McGill, Concordia, UQAM, Université de Montréal, École Polytechnique, INRS, IRICoR, UNIVALOR, CDEC, REPAF and WeWork, 2012-present
  • “Intellectual Property and Commercialization”
  • “Inventorship and Ownership”
  • “Patents and Inventorship in Academia”
  • “Le Brevet : plus qu’une protection, un outil de commercialisation”
  • “Entente de collaboration et propriété intellectuelle”
  • “La protection de l’innovation et les enjeux reliés à la propriété intellectuelle”
• “Patents and Inventorship – The Canadian perspective”, American Chemical Society National Meeting, Chemistry and the Law Division, Indianapolis, IN, September 2013
• “Recent developments in Canadian Patent Law”, American Chemical Society National Meeting, Chemistry and the Law Division, Denver, Co, September 2011
• “Selection Patents alive and well in Canada: the Sanofi decision”, American Chemical Society National Meeting, Chemistry and the Law division, Washington D.C., August 2009
• “Patent Prosecution in Canada: What’s New?”, American Chemical Society national meeting, Chemistry and the Law division, Philadelphia, PE, August 2008
• “A Second Patent on my Patented Compounds: The Law of Selection Patents in Canada”, American Chemical Society national meeting, Chemistry and the Law division, Philadelphia, PE, August 2008
• “Value of a Chemical Patent”, Industrial Chemistry Symposium, Edmonton, AB, May 2008
• “Patenting and Protecting your Life Science Invention”, Health Care Products Association of Manitoba, Winnipeg, MB, June 2007
• “Patenting and Protecting your Chemical Invention”, Intellectual Property Seminar, Chemical Institute of Canada Annual Meeting, Halifax, NS, May 2006; Winnipeg, MB, May 2007; Edmonton, AB, May 2008
• Luu-The, V.; Poirier, D.; T. Ngatcha, Béatrice; Labrie, F. “Characterization of New Potent Inhibitors of Type 3 17ß-Hydroxysteroid Dehydrogenase”, 81st Annual Meeting of the Endocrine Society, San Diego, June 1999
• T. Ngatcha, Béatrice; Luu-The, V.; Labrie, F.; Poirier D. “Androsterone Derivatives Substituted at Position 3: Chemical Synthesis and Inhibitory Activity on Type 3 17ß-Hydroxysteroid Dehydrogenase”, 67th ACFAS Congress, Ottawa, Canada, May 1999
• T. Ngatcha, Béatrice; Luu-The, V.; Labrie, F.; Poirier D. “3ß-Substituted Androsterone Derivatives as Inhibitors of Type 3 17ß-Hydroxysteroid Dehydrogenase”, 217th National American Chemical Society (ACS) Congress, Anaheim, March 1999
• T. Ngatcha, Béatrice; Luu-The, V.; Poirier D. “3a-Ether Derivatives of 3ß-Substituted Androsterone as Inhibitors of Type 3 17ß-Hydroxysteroid Dehydrogenase”, 217th National American Chemical Society (ACS) Congress, Anaheim, March 1999
• Poirier, D.; Maltais, R.; T. Ngatcha, Béatrice; Tremblay, M. “The Combinatorial Chemistry and the Development of Therapeutic Agents: The Case of 17ß-Hydroxysteroid Dehydrogenase Inhibitors”, 40th “Club de Recherche Clinique du Québec”, Mont-Tremblant, Canada, October 1998
• T. Ngatcha, Béatrice; Poirier, D. “Stereoselectivity of the Addition of Organomagnesium Reagents to 17ß-TBDMS-Dihydrostestosterone”, 216th National American Chemical Society Congress, Boston, August 1998
• T. Ngatcha, Béatrice; Labrie, F.; Poirier, D. “Synthesis and Hormonal Profile of Androsterone Derivatives Substituted at Position 16”, 10th International Congress on Hormonal Steroids, Québec City, Canada, June 1998
• Poirier, D.; Tremblay, M.; T. Ngatcha, Béatrice; Dionne, P. “13C NMR Data as a Useful Tool in the Stereochemistry Determination of D-ring Substituted Steroids”, 8th Québec/Ontario Minisymposium in Bio-Organic Chemistry, Québec City, Canada, November 1997
• T. Ngatcha, Béatrice; Luu-The, V.; Poirier, D. “Bromopropyl Androsterone Derivatives as Type 3 17ß-Hydroxysteroid Dehydrogenase Inhibitors”, “Ordre des chimistes du Québec” Congress, Laval, Canada, June 1997
• Dionne, P.; T. Ngatcha, Béatrice; Poirier, D.; Labrie, F. “Estradiol D-Ring Substitution: Analysis by Nuclear Magnetic Resonance (NMR)”, 65th ACFAS Congress, Trois-Rivières, Canada, May 1997
• T. Ngatcha, Béatrice; Luu-The, V.; Poirier, D. “Synthesis of Bromopropyl Androsterone Derivatives”, 65th ACFAS Congress, Trois-Rivières, Canada, May 1997
• T. Ngatcha, Béatrice; Dionne, P.; Poirier, D. “D-Ring Allyl Derivatives of Estradiol: Synthesis and 13C NRM Data”, 7th Québec/Ontario Minisymposium in Bioorganic and Organic Chemistry, Waterloo, Canada, octobre 1996
• T. Ngatcha, Béatrice; Chênevert, R. “Enzymatic Hydrolysis of Citric and Tricarballylic Esters”, 63rd ACFAS Congress, Chicoutimi, Canada, mai 1995

Professional and community activities

• Corporate Secretary of the Advanced Materials Research and Innovation Hub (PRIMA Québec), 2019-present
• Coach and Project Evaluator at Fondation Montréal Inc., 2018-present
• Member of the Board of Directors of Centre des arts de la scène Pauline-Julien, 2019-present
• Member of the group Sistah Girl (black ladies in intellectual property), 2017–present
• Member of “Réseau des Entrepreneurs et Professionnels Africains (REPAF)”, 2017–present
• Mentorship program, University of Ottawa, 2017-present

• Natural Products and Pharmaceutical Innovations: What are the Patent Options?

  By Béatrice T Ngatcha |May 2020

• Natural Products and Pharmaceutical Innovations: What are the Patent Options?